First OTC Low-Dose Brimonidine Eye Drop Approved for Ocular Redness

Share this content:

The Food and Drug Administration (FDA) has approved Lumify 0.025%, the first over-the-counter low-dose brimonidine tartrate ophthalmic solution for the treatment of ocular redness. 

Brimonidine, a selective alpha-2 adrenergic receptor agonist, works by selectively constricting the veins in the eye, increasing the availability of oxygen to surrounding tissue and reducing the likelihood of rebound redness, often associated with non-selective redness reducers. In clinical studies, low-dose brimonidine showed 95% symptom improvement at 1 minute, and reduced redness for up to 8 hours. 

Brimonidine is already approved in higher doses as a prescription eye drop for the treatment of intraocular pressure reduction in glaucoma patients.

Lumify is expected to be available from Bausch + Lomb in the second quarter of 2018.

For more information visit Bausch.com.

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Case Numbers of U.S. Children With Polio-Like Illness Hit Record High

Case Numbers of U.S. Children With Polio-Like Illness ...

CDC says there have been 158 confirmed cases of acute flaccid myelitis in 36 states

Paid Childbearing Policies Lacking for Residents

Paid Childbearing Policies Lacking for Residents

Policies optimizing competing goals and defining training competency needed

is free, fast, and customized just for you!




Already a member?

Sign In Now »